1.Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for T lymphoblastic leukemia/lymphoma.
Lan LUO ; Yang JIAO ; Ping YANG ; Yan LI ; Wen Yang HUANG ; Xiao Yan KE ; De Hui ZOU ; Hong Mei JING
Chinese Journal of Hematology 2023;44(5):388-394
Objective: To analyze the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for treating T lymphoblastic leukemia/lymphoma (T-ALL/LBL) . Methods: This study retrospectively evaluated 119 adolescent and adult patients with T-ALL/LBL from January 2006 to January 2020 at Peking University Third Hospital and Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. Patients were divided into chemotherapy-only, chemotherapy followed by allo-HSCT, and chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) groups according to the consolidation regimen, and the 5-year overall survival (OS) and progression-free survival (PFS) rates of each group were compared. Results: Among 113 patients with effective follow-up, 96 (84.9%) patients achieved overall response (ORR), with 79 (69.9%) having complete response (CR) and 17 (15.0%) having partial response (PR), until July 2022. The analysis of the 96 ORR population revealed that patients without transplantation demonstrated poorer outcomes compared with the allo-HSCT group (5-year OS: 11.4% vs 55.6%, P=0.001; 5-year PFS: 8.9% vs 54.2%, P<0.001). No difference was found in 5-year OS and 5-year PFS between the allo-HSCT and auto-HSCT groups (P=0.271, P=0.197). The same results were achieved in the CR population. Allo-HSCT got better 5-year OS (37.5% vs 0) for the 17 PR cases (P=0.064). Different donor sources did not affect 5-year OS, with sibling of 61.1% vs hap-haploidentical of 63.6% vs unrelated donor of 50.0% (P>0.05). No significant difference was found in the treatment response in the early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP) and non-ETP populations. The ETP group demonstrated lower 5-year OS compared with the non-ETP group in the chemotherapy alone group (0 vs 12.6%, P=0.045), whereas no significant difference was found between the ETP and non-ETP groups in the allo-HSCT group (75.0% vs 62.9%, P=0.852). Multivariate analysis revealed that high serum lactate dehydrogenase level, without transplantation, and no CR after chemotherapy induction were independently associated with inferior outcomes (P<0.05) . Conclusion: Allo-HSCT could be an effective consolidation therapy for adult and adolescent patients with T-ALL/LBL. Different donor sources did not affect survival. Allo-HSCT may overcome the adverse influence of ETP-ALL/LBL on OS.
Adult
;
Adolescent
;
Humans
;
Prognosis
;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
;
Retrospective Studies
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*
;
Hematopoietic Stem Cell Transplantation
;
Lymphoma, T-Cell
;
Unrelated Donors
2.A Case of Acute Lymphoblastic Leukemia in a Patient with Minimal Change Nephrotic Syndrome.
Il Young KIM ; Ji Yoon MOON ; Moo Kon SONG ; Yong Sung AHN ; Kyung Yup KIM ; Young Jin CHOI ; Ho Jin SHIN ; Joo Seop CHUNG ; Goon Jae CHO
Korean Journal of Hematology 2006;41(3):199-203
We experienced a 22-year old patient with a documented history of minimal change nephrotic syndrome (MCNS), and a diagnosis of acute lymphoblastic leukemia (ALL) was then made for this patient. The patient received standard daily steroid therapy for the treatment of nephrotic syndrome. Cyclosporin A was administered because there was no clinical improvement with steroid therapy. Six years after the diagnosis of nephrotic syndrome, the patient was diagnosed with ALL. After chemotherapy for ALL, the patient was in complete remission and he showed clinical improvement of nephrotic syndrome. The hematological malignancies associated with nephrotic syndrome are mainly lymphoma and chronic lymphocytic leukemia. ALL has rarely been described in combination with nephrotic syndrome. Although the exact mechanism for development of ALL after nephrotic syndrome is unknown, at least two possibilities exist. First, the incidence of leukemia may be increased after immunosuppressive therapy, which may include cyclosporin A. Second, the underlying defect in T-lymphocyte function could account for both nephrotic syndrome and ALL. The possible mechanisms for such a relationship are discussed here along with a review of the relevant literature.
Cyclosporine
;
Diagnosis
;
Drug Therapy
;
Hematologic Neoplasms
;
Humans
;
Incidence
;
Leukemia
;
Leukemia, Lymphocytic, Chronic, B-Cell
;
Lymphoma
;
Nephrosis, Lipoid*
;
Nephrotic Syndrome
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
;
T-Lymphocytes
;
Young Adult
3.Clinical Analysis of SET-NUP214 Fusion Gene Positive Patients with Acute Leukemia.
Yang SONG ; Xiao-Yuan GONG ; Shu-Ning WEI ; Qing-Hua LI ; Guang-Ji ZHANG ; Ying WANG ; Hui WEI ; Dong LIN ; Shang-Zhu LI ; Si-Zhou FENG ; Jian-Xiang WANG ; Ying-Chang MI
Journal of Experimental Hematology 2023;31(2):352-357
OBJECTIVE:
To analyze the characteristics and prognosis of acute leukemia(AL) with SET-NUP214 fusion gene.
METHODS:
The clinical data of 17 patients over 14 years old newly diagnosed with SET-NUP214 positive AL admitted in Institute of Hematology and Blood Diseases Hospital from August 2017 to May 2021 were analyzed retrospectively.
RESULTS:
Among the 17 SET-NUP214 positive patients, 13 cases were diagnosed as T-ALL (ETP 3 cases, Pro-T-ALL 6 cases, Pre-T-ALL 3 cases, Medullary-T-ALL 1 case), AML 3 cases (2 cases M5, 1 case M0) and ALAL 1 case. Thirteen patients presented extramedullary infiltration at initial diagnosis. All 17 patients received treatment, and a total of 16 cases achieved complete remission (CR), including 12 cases in patients with T-ALL. The total median OS and RFS time were 23 (3-50) months and 21 (0-48) months, respectively. Eleven patients received allogeneic hematopoietic stem cell transplantation(allo-HSCT), with median OS time of 37.5 (5-50) months and median RFS time of 29.5 (5-48) months. The median OS time of 6 patients in chemotherapy-only group was 10.5 (3-41) months, and median RFS time of 6.5 (3-39) months. The OS and RFS of patients with transplantation group were better than those of chemotherapy-only group (P=0.038). Among the 4 patients who relapsed or refractory after allo-HSCT, the SET-NUP214 fusion gene did not turn negative before transplantation. While, in the group of 7 patients who have not relapsed after allo-HSCT till now, the SET-NUP214 fusion gene expression of 5 patients turned negative before transplantation and other 2 of them were still positive.
CONCLUSION
The fusion site of SET-NUP214 fusion gene is relatively fixed in AL patients, often accompanied by extramedullary infiltration. The chemotherapy effect of this disease is poor, and allo-HSCT may improve its prognosis.
Humans
;
Adolescent
;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
;
Retrospective Studies
;
Leukemia, Myeloid, Acute/therapy*
;
Hematopoietic Stem Cell Transplantation
;
Acute Disease
;
Prognosis
;
Leukemia-Lymphoma, Adult T-Cell/therapy*
;
Nuclear Pore Complex Proteins
4.Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen.
Il Hwan RYU ; In Sung CHO ; Ah Jeong RYU ; Min Gyu KIM ; Jae Woong JEON ; Joo Seok KIM ; Jae Joon LEE ; Ji Wook CHOI ; Dong Wook KANG
Cancer Research and Treatment 2015;47(1):115-119
T-lymphoblastic lymphoma (T-LBL) is a rare form of aggressive non-Hodgkin's lymphoma. The standard approach for management of T-LBL involves intensive multiagent chemotherapy regimens for induction and consolidation phases with central nervous system prophylaxis and a maintenance phase lasting 12-18 months. We report on a case of long-term survival after one cycle of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) and high-dose methotrexate. A 30-year-old woman diagnosed with T-LBL with a large mediastinal mass underwent one cycle of hyper-CVAD. Four days after the start of treatment, the mediastinal mass was markedly reduced. Treatment continued with one cycle of consolidation chemotherapy, comprising high-dose methotrexate and high-dose cytarabine. The patient then refused all further chemotherapeutic treatment. Seven years have passed without relapse.
Adult
;
Central Nervous System
;
Consolidation Chemotherapy
;
Cyclophosphamide
;
Cytarabine
;
Dexamethasone
;
Doxorubicin
;
Drug Therapy
;
Female
;
Humans
;
Lymphoma
;
Lymphoma, Non-Hodgkin
;
Methotrexate
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
;
Recurrence
;
Remission Induction
;
T-Lymphocytes*
;
Vincristine
5.Case series of precursor B-cell lymphoblastic lymphoma.
Jin Yong KIM ; Sang Yong OM ; Su Jin SHIN ; Jeong Eun KIM ; Dok Hyun YOON ; Cheolwon SUH
Blood Research 2014;49(4):270-274
Precursor B-cell lymphoblastic lymphoma (B-LBL) is an uncommon subtype of Non-Hodgkin lymphoma (NHL), accounting for only 0.3% of NHL in adults and less than 10% of all LBL cases. Unlike T-cell LBL, it usually presents with extranodal involvement while sparing the bone marrow (BM). Among the 27 patients with LBL treated in the Asan Medical Center between January 2007 and March 2012, 3 had B-LBL. All had a good performance status and low International Prognostic Index. However, unlike most previously reported cases, the patients had lymphoma in their bone marrow and extranodal sites such as bone and lung. After intensive combination chemotherapy, one patient achieved a complete response and the other 2 patients, a partial response. Our experience suggests that multiple extranodal sites may be involved in B-LBL and BM involvement may not be as infrequent as previously thought. Furthermore, intensive chemotherapy seems to be effective.
Adult
;
Bone Marrow
;
Chungcheongnam-do
;
Drug Therapy
;
Drug Therapy, Combination
;
Humans
;
Lung
;
Lymphoma
;
Lymphoma, Non-Hodgkin
;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*
;
T-Lymphocytes
6.A Case of T-cell Lymphoblastic Lymphoma Involving the Skin.
Min Jung WOO ; Sung Woo LEE ; Sang Won KIM ; Ghil Suk YOON
Korean Journal of Dermatology 2003;41(2):227-231
Lymphoblastic lymphoma(LBL) is non-Hodgkin's lymphoma with a high tendency of rapid progression to acute leukemia, but cutaneous infiltration is rare. Cutaneous lesions in LBL were largely red papules and nodules. We herein report a case of 24-year-old woman with T-cell LBL(TLBL) involving the skin. The lesions revealed 1~3 cm-sized, multiple confluent scaly patches on her face and back, and subsided about 4 weeks later during the period of follow-up and combination chemotherapy. Histologically there were perivascular, periadnexal and perineural infiltrates of medium-sized lymphoid cells in mid to deep dermis. The neoplastic cells had scant cytoplasm, very fine chromatin, and inconspicuous nucleoli and expressed CD5, CD45, CD45RO and TdT.
Chromatin
;
Cytoplasm
;
Dermis
;
Drug Therapy, Combination
;
Female
;
Follow-Up Studies
;
Humans
;
Leukemia
;
Lymphocytes
;
Lymphoma, Non-Hodgkin
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
;
Skin*
;
T-Lymphocytes*
;
Young Adult
7.Research Advances in the Treatment of B-Cell Acute Lymphoblastic Leukemia Based on Surface Antigen Expression --Review.
Journal of Experimental Hematology 2021;29(2):648-652
B-cell acute lymphoblastic leukemia (B-ALL) is a common malignant tumor in hematopoietic system. Although the remission rate of the patients with adult B-ALL is similar to those with childhood B-ALL, the rate of long-term disease-free survival (DFS) rate is significantly lower, once recurrence, the remission rate of routine chemotherapy is low and the prognosis is so poor. Based on the expression of tumor cell surface antigens(such as CD19, CD20 and CD22), the specific monoclonal antibodies, bispecific antibodies and chimeric antigen receptor T cells (CAR-T), and other targeted immunotherapy can greatly improve the efficacy of B-ALL patients, especially for patients with relapse and refractory. In this review, the progress of immunotherapy against B-ALL cell surface antigen is summarized briefly.
Adult
;
Antigens, CD19
;
Antigens, Surface
;
B-Lymphocytes
;
Burkitt Lymphoma
;
Child
;
Humans
;
Immunotherapy, Adoptive
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*
;
Receptors, Antigen, T-Cell
8.Treatment and Prognosis of Adult T Cell Acute Lymphoblastic Leukemia.
Zou Fang HUANG ; Ting Yu WANG ; Ming Wei FU ; Wei LIU ; Mu HAO ; Lu Gui QIU ; De Hui ZOU
Acta Academiae Medicinae Sinicae 2019;41(4):485-491
To analyze the treatment and prognosis of T cell acute lymphoblastic leukemia(T-ALL)in adults. Method The clinicobiogical and survival data of 68 adult patients with newly diagnosis T-ALL were retrospectively analzyed. Results The median age of these 68 patients was 23 years(14-60 years).T-ALL was more common in men(81%).After the first cycle of treatment,complete remission was achieved in 50 patients(73%).The highest complete remission(CR) rate was in patients with cortex T-ALL(100%),followed by other T-ALL(73%)and early T-cell precursor lymphoblastic leukemia(54%),(=5.712,=0.058).The CR rate for adults aged >35 years was significantly lower than that of patients aged ≤ 35 years(40% 79%,=6.364,=0.012).The overall CR rate after the second treatment course was 93%.For patients treated with chemotherapy,autograft hematopoietic stem cell transplantation(auto-SCT),and allogeneic SCT,the median relapse free survival was 10 months,24 months,and not reached,respectively(=0.002).The 5-year overall survival rate was 25% for all patients;for patients treated with chemotherapy,auto-SCT and allogeneic SCT,the median overall survival was 24 months,34 months,and 30 months,respectively(=0.007),and the 5-year overall survival rate was 9%,33%,and 38%(=0.037).Multivariate analysis showed leukocyte count ≥100×10 /L was a risk factor for decreased relapse free survival(risk ratio 2.540,95%=1.058-6.099,=0.037). Conclusion Adult T-ALL patients have poor prognosis,which may be improved by SCT.
Adolescent
;
Adult
;
Disease-Free Survival
;
Female
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Male
;
Middle Aged
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
diagnosis
;
therapy
;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
;
diagnosis
;
therapy
;
Prognosis
;
Remission Induction
;
Retrospective Studies
;
Survival Rate
;
Treatment Outcome
;
Young Adult
9.A Case of Adult T-cell Leukemia/Lymphoma.
Jin Young JUNG ; Hee Jung LEE ; Ju Hee LEE ; Kwang Hoon LEE
Korean Journal of Dermatology 2007;45(1):58-62
Adult T-cell leukemia/lymphoma (ATLL) is a human malignancy associated with human T-cell leukemia virus type I (HTLV-I), which frequently involves the skin. ATLL can be diagnosed based on clinicopathological findings and the presence of anti-HTLV-I serum antibodies and monoclonal integrated HTLV-I provirus in the DNA of tumor cells. It is characterized by leukemia, lymphadenopathy, hypercalcemia, and lytic bone lesions. We report a case of ATLL in a 59-year-old man who developed multiple, scattered papules on the face and trunk. He had a 3-month history of melena. The physical examination showed multiple cervical and axillary lymph node enlargements. On laboratory investigation, the white blood cell count was 113,900/mm(3) with 70% atypical lymphocytes. Histopathological and immunohistochemical analyses of a skin and stomach biopsy confirmed the diagnosis of T-cell lymphoma. Final diagnosis of ATLL was made based on HTLV-I positivity. The patient underwent multiple cycles of combination chemotherapy and combination therapy of zidovudine and interferon-alpha which produced some improvement, but he died of pulmonary complications 3 months after the initial diagnosis.
Adult*
;
Antibodies
;
Biopsy
;
Diagnosis
;
DNA
;
Drug Therapy, Combination
;
Human T-lymphotropic virus 1
;
Humans
;
Hypercalcemia
;
Interferon-alpha
;
Leukemia
;
Leukemia, T-Cell
;
Leukemia-Lymphoma, Adult T-Cell
;
Leukocyte Count
;
Lymph Nodes
;
Lymphatic Diseases
;
Lymphocytes
;
Lymphoma, T-Cell
;
Melena
;
Middle Aged
;
Physical Examination
;
Proviruses
;
Skin
;
Stomach
;
T-Lymphocytes*
;
Zidovudine